Biopharmaceutical drug targeting to the brain

Journal of Drug Targeting

Volumn 18, Issue 3, 2010, Pages 157-167

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Drug targeting; Insulin receptor; Monoclonal antibody

Indexed keywords

AMINO ACID DECARBOXYLASE; ANG 1005; ANGIOPEP 2; ANGIOPEPTIN; AVIDIN; BRAIN DERIVED NEUROTROPHIC FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; GLIAL DERIVED NEUROTROPHIC FACTOR; GLUCOSE TRANSPORTER; GLUTAMATE DECARBOXYLASE; HYBRID PROTEIN; IMMUNOGLOBULIN G; INSULIN; INSULIN RECEPTOR; LEVODOPA; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSOSOME ENZYME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX26; NEUROTROPHIC FACTOR; PACLITAXEL; PLASMID DNA; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ENZYME; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; CANCER DIAGNOSIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TRANSPORT; DRUG TREATMENT FAILURE; DRUG UPTAKE; ENDOCYTOSIS; ENZYME SUBSTRATE; GENE FUSION; GENETIC ENGINEERING; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLYCEMIC CONTROL; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOLECULAR CLONING; NERVE SPROUTING; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN TARGETING; RECEPTOR AFFINITY; REVIEW; STROKE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYMES; HUMANS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77949375780     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903548354     Document Type: Review

References (78)

1. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med, 6: 916-919.
2. Barinaga M. (1994). Neurotrophic factors enter the clinic. Science, 264: 772-774.
3. Bickel U, Kang YS, Yoshikawa T, Pardridge WM. (1994). In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem, 42: 1493-1497.
4. Blasberg RG, Patlak C, Fenstermacher JD. (1975). Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther, 195: 73-83.
5. Boado RJ, Pardridge WM. (2009a). Genetic engineering of IgGglucuronidase fusion proteins. J Drug Target, in press.
6. Boado RJ, Pardridge WM. (2009b). Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos, 37: 2299-2304.
7. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. (2007a). Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng, 96: 381-391.
8. Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. (2007b). Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem, 18: 447-455.
9. Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. (2008a). GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng, 100: 387-396.
10. Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. (2008b). Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng, 99: 475-484.
11. Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. (2008c). IgGparaoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm, 5: 1037-1043.
12. Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. (2008d). Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem, 19: 731-739.
13. Boado RJ, Zhang Y, Wang Y, Pardridge WM. (2009a). Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng, 102: 1251-1258.
14. Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardridge WM. (2009b). Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin Receptor. Mol Pharm, in press.
15. Boado RJ, Hui EK, Lu JZ, Pardridge WM. (2009c). AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol, 144: 135-141.
16. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo JM, Chamorro A, Desmet A; European-Australian Fiblast (Trafermin) in Acute Stroke Group. (2002). Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis, 14: 239-251.
17. Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. (2000). Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res, 17: 266-274.
18. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W. (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood, 112: 3303-3311.
19. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA, 98: 8850-8855.
20. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. (2005). Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res, 46: 1239-1247.
21. Duffy KR, Pardridge WM. (1987). Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res, 420: 32-38.
22. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. (2002). Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med, 8: 495-505.
23. Eketjäll S, Fainzilber M, Murray-Rust J, Ibáñez CF. (1999). Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. EMBO J, 18: 5901-5910.
24. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D. (2005). Continuous lowlevel glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci, 25: 769-777.
25. Fisher M, Meadows ME, Do T, Weise J, Trubetskoy V, Charette M, Finklestein SP. (1995). Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab, 15: 953-959.
26. Glenner GG, Wong CW. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun, 120: 885-890.
27. Green NM. (1975). Avidin. Adv Protein Chem, 29: 85-133.
28. He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D. (2005). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci, 25: 619-628.
29. Hendrickson WA, Pähler A, Smith JL, Satow Y, Merritt EA, Phizackerley RP. (1989). Crystal structure of core streptavidin determined from multiwavelength anomalous diffraction of synchrotron radiation. Proc Natl Acad Sci USA, 86: 2190-2194.
30. Hui EK, Boado RJ, Pardridge WM. (2009). Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm, 6: 1536-1543.
31. Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. (2002). Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia, 40: 195-205.
32. Kitagawa H, Hayashi T, Mitsumoto Y, Koga N, Itoyama Y, Abe K. (1998). Reduction of ischemic brain injury by topical application of glial cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. Stroke, 29: 1417-1422.
33. Knoblach SM, Fan L, Faden AI. (1999). Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol, 95: 115-125.
34. Kurihara A, Pardridge WM. (1999). Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res, 59: 6159-6163.
35. Kyle JW, Birkenmeier EH, Gwynn B, Vogler C, Hoppe PC, Hoffmann JW, Sly WS. (1990). Correction of murine mucopolysaccharidosis VII by a human beta-glucuronidase transgene. Proc Natl Acad Sci USA, 87: 3914-3918.
36. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol, 59: 459-466.
37. Lapchak PA, Miller PJ, Collins F, Jiao S. (1997). Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience, 78: 61-72.
38. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. (2004). Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol, 56: 468-477.
39. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. (2000). Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther, 292: 1048-1052.
40. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. (2002). Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab, 22: 223-231.
41. Lieutaud T, Andrews PJ, Rhodes JK, Williamson R. (2008). Characterization of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1beta and MIP-2 in rats. J Neurotrauma, 25: 1179-1185.
42. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 260: 1130-1132.
43. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA, 82: 4245-4249.
44. Méresse S, Delbart C, Fruchart JC, Cecchelli R. (1989). Low-density lipoprotein receptor on endothelium of brain capillaries. J Neurochem, 53: 340-345.
45. Nazer B, Hong S, Selkoe DJ. (2008). LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis, 30: 94-102.
46. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 60: 69-73.
47. Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR. (2008). Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol Ther, 16: 1459-1466.
48. Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. (2004). Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci, 117: 5071-5078.
49. Pardridge WM, Boado RJ. (2009). Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res, 26: 2227-2236.
50. Pardridge WM, Buciak JL, Friden PM. (1991). Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther, 259: 66-70.
51. Pardridge WM, Kang YS, Buciak JL, Yang J. (1995). Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res, 12: 807-816.
52. Pardridge WM, Mietus LJ. (1980). Palmitate and cholesterol transport through the blood-brain barrier. J Neurochem, 34: 463-466.
53. Pardridge WM. (1991). Peptide Drug Delivery to the Brain. New York: Raven Press.
54. Pardridge WM. (2001). Brain Drug Targeting: The Future of Brain Drug Development. Cambridge, UK: Cambridge University Press.
55. Pardridge WM. (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx, 2: 3-14.
56. Pardridge WM. (2008). Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem, 19: 1327-1338.
57. Pardridge WM. (2009). Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement, 5: 427-432.
58. Prince WS, McCormick LM, Wendt DJ, Fitzpatrick PA, Schwartz KL, Aguilera AI, Koppaka V, Christianson TM, Vellard MC, Pavloff N, Lemontt JF, Qin M, Starr CM, Bu G, Zankel TC. (2004). Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase. J Biol Chem, 279: 35037-35046.
59. Reiber H, Felgenhauer K. (1987). Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta, 163: 319-328.
60. Ron D, Janak PH. (2005). GDNF and addiction. Rev Neurosci, 16: 277-285.
61. Ruth L, Eisenberg D, Neufeld EF. (2000). alpha-L-iduronidase forms semi-crystalline spherulites with amyloid-like properties. Acta Crystallogr D Biol Crystallogr, 56: 524-528.
62. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, Gerhardt GA, Gash DM. (2006). Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol, 202: 497-505.
63. Scott HS, Anson DS, Orsborn AM, Nelson PV, Clements PR, Morris CP, Hopwood JJ. (1991). Human alpha-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci USA, 88: 9695-9699.
64. Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa R, Nakamura K, Shitara K. (2006). Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem, 140: 777-783.
65. Skarlatos S, Yoshikawa T, Pardridge WM. (1995). Transport of [125I] transferrin through the rat blood-brain barrier. Brain Res, 683: 164-171.
66. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. (1997). Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA, 94: 4109-4112.
67. Song BW, Vinters HV, Wu D, Pardridge WM. (2002). Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther, 301: 605-610.
68. Spencer BJ, Verma IM. (2007). Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci USA, 104: 7594-7599.
69. Suzuki T, Wu D, Schlachetzki F, Li JY, Boado RJ, Pardridge WM. (2004). Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med, 45: 1766-1775.
70. The BDNF Study Group. (1999). A controlled trial of recombinant methionyl human BDNF in ALS (Phase III). Neurology, 52: 1427-1433.
71. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR, Smith QR. (2009). Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res, 26: 2486-2494.
72. Triguero D, Buciak J, Pardridge WM. (1990). Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem, 54: 1882-1888.
73. Wu D, Pardridge WM. (1996). Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a bloodbrain barrier drug delivery system. J Pharmacol Exp Ther, 279: 77-83.
74. Wu D, Pardridge WM. (1999). Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA, 96: 254-259.
75. Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA. (1994). Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol, 127: 23-36.
76. Zhang Y, Pardridge WM. (2001a). Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res, 889: 49-56.
77. Zhang Y, Pardridge WM. (2001b). Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brainderived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke, 32: 1378-1384.
78. Zivin JA. (1998). Factors determining the therapeutic window for stroke. Neurology, 50: 599-603.